# Myriad Genetics

Source: https://onco.cc/companies/myriad-genetics/  
OnCo record `myriad-genetics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The company that made BRCA testing a business, now selling hereditary panels and the myChoice, EndoPredict and Prolaris tumour tests.

## Summary

Myriad held the BRCA1/2 gene patents until the 2013 US Supreme Court ruling and launched BRACAnalysis CDx (2014) and myChoice CDx (2019), the two FDA-approved companion diagnostics for PARP inhibitors. MyRisk is its hereditary cancer panel; EndoPredict (breast) and Prolaris (prostate) are its prognostic tests. Its history is a case study in how gene patents, guidelines and reimbursement shape which tests patients receive.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Salt Lake City, UT
- Type: diagnostics
- Website: https://myriad.com
- Ticker: MYGN

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Myriad_Genetics
- Official website: https://myriad.com

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Prevention & Risk](https://onco.cc/fronts/prevention/)
- technologies: [Companion diagnostics](https://onco.cc/technologies/companion-diagnostic/), [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/), [HRD & BRCA testing](https://onco.cc/technologies/hrd-testing/), [HRD genomic scar scores (GIS, LOH, HRDetect)](https://onco.cc/technologies/hrd-genomic-scar-scores/)
- drugs: [BRACAnalysis CDx](https://onco.cc/drugs/bracanalysis-cdx/), [EndoPredict](https://onco.cc/drugs/endopredict/), [myChoice CDx](https://onco.cc/drugs/mychoice-cdx/), [Prolaris](https://onco.cc/drugs/prolaris/)
- trials: [SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors](https://onco.cc/trials/nct05642780/)
- key papers: [Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer](https://onco.cc/key-papers/paper-telli-hrd-score-platinum-tnbc-ccr-2016/)
- ideas: [Test every man for DNA repair faults on the day his prostate cancer is found to have spread, not three treatments later](https://onco.cc/ideas/idea-prostate-hrr-testing-at-metastatic-diagnosis/)
- terms: [Association for Molecular Pathology v. Myriad Genetics (2013)](https://onco.cc/terms/myriad-ruling/)
- roadmaps: [Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers](https://onco.cc/roadmaps/prevention-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/myriad-genetics.json